Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIO-TECHNE CorpTECH · Entity 3479 | Director · Chief Executive Officer | August 15, 2023 | August 17, 2023 |
| Gentherm IncTHRM · Entity 4845 | Director | May 14, 2026 | May 15, 2026 |
| Orthofix Medical Inc.OFIX · Entity 1975 | Director | June 10, 2026 | June 12, 2026 |
| Quantum-Si IncQSI · Entity 6440 | Director | May 18, 2026 | May 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIO-TECHNE Corp
Report date August 15, 2023 · Filed August 17, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,278,269 |
Last balance in matching sequence
After 2023-08-15 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2023-08-15 · Exercise / conversion · Acquired 17,632 · Balance 1,286,944 F1: Includes 7,128 shares of restricted stock for which the risk of forfeiture will lapse on August 6, 2024. Row 2 · 2023-08-15 · Tax withholding · Disposed 8,675 · Balance 1,278,269 F1: Includes 7,128 shares of restricted stock for which the risk of forfeiture will lapse on August 6, 2024. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 59,095 |
Reported balance
After 2023-08-15 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2023-08-15 · Grant · Acquired 59,095 · Balance 59,095 F3: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F9: 19,698 shares vest on each of 8/15/2024 and 8/15/2026, and 19,699 shares vest on 8/15/2025. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 35,268 |
Reported balance
Holding disclosure · report date 2023-08-15 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance 35,268 F3: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F4: 17,636 shares vest on 8/15/2024 and 17,632 shares vest on 8/15/2025. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 32,064 |
Reported balance
Holding disclosure · report date 2023-08-15 · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · Balance 32,064 F3: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F6: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
| Common StockSEC Table I · non-derivative | IndirectBy Step-Son | 400 |
Reported balance
Holding disclosure · report date 2023-08-15 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 400 |
| Common StockSEC Table I · non-derivative | IndirectBy Step-Daughter | 400 |
Reported balance
Holding disclosure · report date 2023-08-15 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 400 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.26 · Expires 2024-08-09 | Direct | 779,084 |
Reported balance
Holding disclosure · report date 2023-08-15 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 779,084 F2: Fully exercisable. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.33 · Expires 2025-08-08 | Direct | 361,336 |
Reported balance
Holding disclosure · report date 2023-08-15 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 361,336 F2: Fully exercisable. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.33 · Expires 2025-08-08 | Direct | 240,888 |
Reported balance
Holding disclosure · report date 2023-08-15 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 240,888 F2: Fully exercisable. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.60 · Expires 2026-08-07 | Direct | 342,900 |
Reported balance
Holding disclosure · report date 2023-08-15 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 342,900 F2: Fully exercisable. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.60 · Expires 2026-08-07 | Direct | 228,600 |
Reported balance
Holding disclosure · report date 2023-08-15 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 228,600 F2: Fully exercisable. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.97 · Expires 2027-08-05 | Direct | 66,600 |
Reported balance
Holding disclosure · report date 2023-08-15 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 66,600 F2: Fully exercisable. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.97 · Expires 2027-08-05 | Direct | 299,768 |
Reported balance
Holding disclosure · report date 2023-08-15 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 299,768 F2: Fully exercisable. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.97 · Expires 2027-08-05 | Direct | 153,180 |
Reported balance
Holding disclosure · report date 2023-08-15 · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · Balance 153,180 F5: Options to purchase 38,292 shares vest on 8/5/21 and options to purchase 38,296 shares vest on each of 8/5/22, 8/5/23 and 8/5/24. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $120.46 · Expires 2028-08-06 | Direct | 125,260 |
Reported balance
Holding disclosure · report date 2023-08-15 · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · Balance 125,260 F6: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $120.46 · Expires 2028-08-06 | Direct | 83,504 |
Reported balance
Holding disclosure · report date 2023-08-15 · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · Balance 83,504 F7: Options to purchase 20,876 shares vest on each of 8/6/2022, 8/6/2023, 8/6/2024 and 8/6/2025. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $94.52 · Expires 2029-08-15 | Direct | 600,000 |
Reported balance
Holding disclosure · report date 2023-08-15 · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · Balance 600,000 F8: 600,000 options vest in full or in part on 7/1/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 7,128 shares of restricted stock for which the risk of forfeiture will lapse on August 6, 2024.
F2: Fully exercisable.
F3: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
F4: 17,636 shares vest on 8/15/2024 and 17,632 shares vest on 8/15/2025.
F5: Options to purchase 38,292 shares vest on 8/5/21 and options to purchase 38,296 shares vest on each of 8/5/22, 8/5/23 and 8/5/24.
F6: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F7: Options to purchase 20,876 shares vest on each of 8/6/2022, 8/6/2023, 8/6/2024 and 8/6/2025.
F8: 600,000 options vest in full or in part on 7/1/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F9: 19,698 shares vest on each of 8/15/2024 and 8/15/2026, and 19,699 shares vest on 8/15/2025.
Gentherm Inc
Report date May 14, 2026 · Filed May 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,937 |
Reported balance
After 2026-05-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-14 · Grant · Acquired 4,292 · Balance 25,937 F1: The shares represent Restricted Common Stock issued under the 2023 Equity Incentive Plan that has been granted to the Reporting Person as compensation for serving on the Gentherm Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares represent Restricted Common Stock issued under the 2023 Equity Incentive Plan that has been granted to the Reporting Person as compensation for serving on the Gentherm Board of Directors.
Orthofix Medical Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 76,305 |
Reported balance
After 2026-06-10 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 14,965 · Balance 76,305 F1: Represents an award of deferred stock units that vest in full on the first anniversary of the grant date, subject to the reporting person's service through such date. Each deferred stock unit represents a contingent right to receive one share of common stock of the issuer. Vested deferred stock units will settle and convert into common stock within 45 days of the reporting person's termination of service with the issuer. F2: Includes 42,343 previously reported deferred stock units and an aggregate of 2,103 shares acquired under Orthofix's Stock Purchase Plan ("Orthofix's SPP") on 10/31/2025 and 4/30/2026. Orthofix's SPP is a "Stock Purchase Plan" as defined in Rule 16b-3(b)(5), and share acquisitions under the plan are exempt from Section 16(b). |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of deferred stock units that vest in full on the first anniversary of the grant date, subject to the reporting person's service through such date. Each deferred stock unit represents a contingent right to receive one share of common stock of the issuer. Vested deferred stock units will settle and convert into common stock within 45 days of the reporting person's termination of service with the issuer.
F2: Includes 42,343 previously reported deferred stock units and an aggregate of 2,103 shares acquired under Orthofix's Stock Purchase Plan ("Orthofix's SPP") on 10/31/2025 and 4/30/2026. Orthofix's SPP is a "Stock Purchase Plan" as defined in Rule 16b-3(b)(5), and share acquisitions under the plan are exempt from Section 16(b).
Quantum-Si Inc
Report date May 18, 2026 · Filed May 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.85 · Expires 2036-05-18 | Direct | 251,185 |
Reported balance
After 2026-05-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-18 · Grant · Acquired 251,185 · Balance 251,185 F1: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to continued service through the applicable vesting date. |
| Class A Common StockSEC Table I · non-derivative | Direct | 855,000 |
Reported balance
Holding disclosure · report date 2026-05-18 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 855,000 |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to continued service through the applicable vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SPARTON CORP
Report date March 04, 2019 · Filed March 04, 2019
Section 16 reporting ended · disclosed 2019-03-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-03-04 transaction · row 1
1 source rowRow 1 · 2019-03-04 · Disposition to issuer · Disposed 16,197 · Balance 0 F1: Disposed of pursuant to Agreement and Plan of Merger dated as of December 11, 2018, by and among Sparton Corporation, Sparton Parent, Inc. and Striker Merger Sub 2018, Inc. in exchange for $18.50 per share in cash, without interest. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to Agreement and Plan of Merger dated as of December 11, 2018, by and among Sparton Corporation, Sparton Parent, Inc. and Striker Merger Sub 2018, Inc. in exchange for $18.50 per share in cash, without interest.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 12, 2026 22:30 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | GrantCommon Stock | 14,965 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-269871 · ownership.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,305 F1 · shares: Represents an award of deferred stock units that vest in full on the first anniversary of the grant date, subject to the reporting person's service through such date. Each deferred stock unit represents a contingent right to receive one share of common stock of the issuer. Vested deferred stock units will settle and convert into common stock within 45 days of the reporting person's termination of service with the issuer. F2 · balance_after: Includes 42,343 previously reported deferred stock units and an aggregate of 2,103 shares acquired under Orthofix's Stock Purchase Plan ("Orthofix's SPP") on 10/31/2025 and 4/30/2026. Orthofix's SPP is a "Stock Purchase Plan" as defined in Rule 16b-3(b)(5), and share acquisitions under the plan are exempt from Section 16(b). Read SEC document |
| May 18, 2026 Filed May 20, 2026 20:05 UTC | Quantum-Si Inc QSI · Entity 6440 | GrantStock Option (right to buy) · Derivative | 251,185 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001140361-26-022241 · form4.xml · derivative · entry 2 Kummeth Charles R. · CIK 0001534980 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 251,185 Underlying: Class A Common Stock · 251,185 shares Expires 2036-05-18 F1 · derivative.exercise_date: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to continued service through the applicable vesting date. Read SEC document |
| May 14, 2026 Filed May 15, 2026 21:38 UTC | Gentherm Inc THRM · Entity 4845 | GrantCommon Stock | 4,292 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-227290 · ownership.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,937 F1 · security: The shares represent Restricted Common Stock issued under the 2023 Equity Incentive Plan that has been granted to the Reporting Person as compensation for serving on the Gentherm Board of Directors. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 10:01 UTC | Quantum-Si Inc QSI · Entity 6440 | PurchaseClass A Common Stock | 500,000 | $0.92 | $459,800.00 |
DisclosureSEC source: 0001140361-26-008322 · form4.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 855,000 F1 · price: Represents the weighted average purchase price per share. The shares were purchased at prices ranging from $0.8906 to $0.9735 per share. Full information regarding the number of shares purchased at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 20:17 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | GrantCommon Stock | 18,841 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-088993 · ownership.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,237 F1 · shares: Represents an award of deferred stock units that vest in full on the first anniversary of the grant date, subject to the reporting person's service through such date. Each deferred stock unit represents a contingent right to receive one share of common stock of the issuer. Vested deferred stock units will settle and convert into common stock within 45 days of the reporting person's termination of service with the issuer. F2 · balance_after: Includes 23,502 previously reported deferred stock units and an aggregate of 1,894 shares acquired under Orthofix's Stock Purchase Plan on 10/31/2024 and 4/30/2025.. Read SEC document |
| May 19, 2025 Filed May 21, 2025 20:01 UTC | Quantum-Si Inc QSI · Entity 6440 | GrantStock Option (right to buy) · Derivative | 126,095 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001140361-25-020047 · form4.xml · derivative · entry 2 Kummeth Charles R. · CIK 0001534980 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,095 Underlying: Class A Common Stock · 126,095 shares Expires 2035-05-19 F1 · derivative.exercise_date: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to continued service through the applicable vesting date. Read SEC document |
| May 08, 2025 Filed May 9, 2025 20:50 UTC | Gentherm Inc THRM · Entity 4845 | GrantCommon Stock | 5,075 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-068169 · ownership.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,645 F1 · security: The shares represent Restricted Common Stock issued under the 2023 Equity Incentive Plan that has been granted to the Reporting Person as compensation for serving on the Gentherm Board of Directors. Read SEC document |
| August 12, 2024 Filed Aug 13, 2024 10:01 UTC | Quantum-Si Inc QSI · Entity 6440 | PurchaseClass A Common Stock | 31,100 | $0.89 | $27,532.83 |
DisclosureSEC source: 0001140361-24-036919 · form4.xml · nonDerivative · entry 2 Kummeth Charles R. · CIK 0001534980 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 355,000 F2 · price: Represents the weighted average purchase price per share. The shares were purchased at prices ranging from $0.84 to $0.90 per share. Full information regarding the number of shares purchased at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 09, 2024 Filed Aug 13, 2024 10:01 UTC | Quantum-Si Inc QSI · Entity 6440 | PurchaseClass A Common Stock | 138,900 | $0.87 | $120,926.34 |
DisclosureSEC source: 0001140361-24-036919 · form4.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 323,900 F1 · price: Represents the weighted average purchase price per share. The shares were purchased at prices ranging from $0.85 to $0.89 per share. Full information regarding the number of shares purchased at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 11:07 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | GrantCommon Stock | 15,152 | $12.87 | $195,006.24 |
DisclosureSEC source: 0000950170-24-075305 · ownership.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,502 F1 · shares: Represents an award of deferred stock units that vest in full on the first anniversary of the grant date, subject to the reporting person's service through such date. Each deferred stock unit represents a contingent right to receive one share of common stock of the issuer. Vested deferred stock units will settle and convert into common stock within 45 days of the reporting person's termination of service with the issuer. F2 · balance_after: Includes 23,502 deferred stock units. Read SEC document |
| June 07, 2024 Filed Jun 7, 2024 20:41 UTC | Quantum-Si Inc QSI · Entity 6440 | GrantStock Option (Right to buy) · Derivative | 113,281 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001140361-24-029298 · form4.xml · derivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,281 Underlying: Class A Common Stock · 113,281 shares Expires 2034-06-07 F1 · derivative.exercise_date: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to Mr. Kummeth's continued service through the applicable vesting date. Read SEC document |
| May 28, 2024 Filed May 30, 2024 20:47 UTC | Quantum-Si Inc QSI · Entity 6440 | GrantStock Option (Right to buy) · Derivative | 527,777 | $0.00 Strike: $1.58 | $0.00 |
DisclosureSEC source: 0001140361-24-028148 · form4.xml · derivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 527,777 Underlying: Class A Common Stock · 527,777 shares Expires 2034-05-28 F1 · derivative.exercise_date: The shares underlying this option vest in three equal annual installments beginning May 28, 2025, subject to Mr. Kummeth's continued service through the applicable vesting date. Read SEC document |
| May 16, 2024 Filed May 20, 2024 20:59 UTC | Gentherm Inc THRM · Entity 4845 | GrantCommon Stock | 2,662 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-062513 · ownership.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,570 F1 · security: The shares represent Restricted Common Stock issued under the 2023 Equity Incentive Plan that has been granted to the Reporting Person as compensation for serving on the Gentherm Board of Directors. Read SEC document |
| January 31, 2024 Filed Mar 12, 2024 20:29 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | GrantCommon Stock | 8,350 | $13.89 | $115,981.50 |
DisclosureSEC source: 0000950170-24-029983 · ownership.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,350 F1 · shares: Represents an award of deferred stock units that vest in full on the earlier of (i) June 30, 2024 or (ii) the date on which the issuer holds its 2024 annual meeting of stockholders, subject to the reporting person's service through such date. Each deferred stock unit represents a contingent right to receive one share of common stock of the issuer. Vested deferred stock units will settle and convert into common stock within 45 days of the reporting person's termination of service with the issuer. Read SEC document |
| December 18, 2023 Filed Dec 21, 2023 00:07 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | GrantStock Option (right to buy) · Derivative | 47,652 | $0.00 Strike: $13.06 | $0.00 |
DisclosureSEC source: 0001209191-23-059391 · doc4.xml · derivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,652 Underlying: Common Stock · 47,652 shares Expires 2033-12-18 F1 · derivative.exercise_date: The stock options vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, December 18, 2023. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 20:14 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 59,095 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-016707 · form4.xml · derivative · entry 18 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,095 Underlying: Common Stock · 59,095 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F9 · derivative.exercise_date: 19,698 shares vest on each of 8/15/2024 and 8/15/2026, and 19,699 shares vest on 8/15/2025. F9 · derivative.expiration_date: 19,698 shares vest on each of 8/15/2024 and 8/15/2026, and 19,699 shares vest on 8/15/2025. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 20:14 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 8,675 | $84.61 | $733,991.75 |
DisclosureSEC source: 0001062993-23-016707 · form4.xml · nonDerivative · entry 2 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,278,269 F1 · balance_after: Includes 7,128 shares of restricted stock for which the risk of forfeiture will lapse on August 6, 2024. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 20:14 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 17,632 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-016707 · form4.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,286,944 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 7,128 shares of restricted stock for which the risk of forfeiture will lapse on August 6, 2024. Read SEC document |
| August 09, 2023 Filed Aug 11, 2023 20:13 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GiftCommon Stock | 9,008 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-016265 · form4.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,269,312 F1 · ownership.direct: Includes 7,128 shares of restricted stock for which the risk of forfeiture will lapse on August 6, 2024. Read SEC document |
| August 05, 2023 Filed Aug 8, 2023 21:31 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 51,516 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-016040 · form4.xml · derivative · entry 12 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 51,516 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F4 · derivative.exercise_date: On 8/5/2023, the Board of Directors certified vesting of 51,516 performance RSUs. F4 · derivative.expiration_date: On 8/5/2023, the Board of Directors certified vesting of 51,516 performance RSUs. Read SEC document |
| August 05, 2023 Filed Aug 8, 2023 21:31 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 31,962 | $82.17 | $2,626,317.54 |
DisclosureSEC source: 0001062993-23-016040 · form4.xml · nonDerivative · entry 2 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,278,320 F1 · ownership.direct: Includes 7,128 shares of restricted stock for which the risk of forfeiture will lapse on August 6, 2024. Read SEC document |
| August 05, 2023 Filed Aug 8, 2023 21:31 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 51,516 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-016040 · form4.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,310,282 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.direct: Includes 7,128 shares of restricted stock for which the risk of forfeiture will lapse on August 6, 2024. Read SEC document |
| July 21, 2023 Filed Jul 25, 2023 21:27 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 80,000 | $88.36 | $7,069,024.00 |
DisclosureSEC source: 0001062993-23-015315 · form4.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,258,766 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.00 to $88.95 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: Includes (i) 11,448 shares of restricted stock for which the risk of forfeiture will lapse on August 5, 2023; and (ii) 14,248 shares of restricted stock for which the risk of forfeiture will lapse as to 7,128 shares on each of August 6, 2023 and August 6, 2024. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 22:38 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to Buy) · Derivative | 616,676 | $0.00 Strike: $26.65 | $0.00 |
DisclosureSEC source: 0001062993-23-014515 · form4.xml · derivative · entry 5 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 616,676 shares Expires 2023-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 22:38 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 390,727 | $81.63 | $31,895,045.01 |
DisclosureSEC source: 0001062993-23-014515 · form4.xml · nonDerivative · entry 2 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,338,766 F1 · ownership.direct: Includes (i) 11,448 shares of restricted stock for which the risk of forfeiture will lapse on August 5, 2023; and (ii) 14,248 shares of restricted stock for which the risk of forfeiture will lapse as to 7,128 shares on each of August 6, 2023 and August 6, 2024. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 22:38 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 616,676 | $26.65 | $16,434,415.40 |
DisclosureSEC source: 0001062993-23-014515 · form4.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,729,493 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.direct: Includes (i) 11,448 shares of restricted stock for which the risk of forfeiture will lapse on August 5, 2023; and (ii) 14,248 shares of restricted stock for which the risk of forfeiture will lapse as to 7,128 shares on each of August 6, 2023 and August 6, 2024. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:07 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 322 | $83.00 | $26,726.00 |
DisclosureSEC source: 0001062993-23-013263 · form4.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,112,817 F1 · ownership.direct: Includes (i) 11,448 shares of restricted stock for which the risk of forfeiture will lapse on August 5, 2023; and (ii) 14,248 shares of restricted stock for which the risk of forfeiture will lapse as to 7,128 shares on each of August 6, 2023 and August 6, 2024. Read SEC document |
| May 18, 2023 Filed May 22, 2023 20:24 UTC | Gentherm Inc THRM · Entity 4845 | GrantCommon Stock | 2,147 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-031459 · doc4.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,908 F1 · security: The shares represent Restricted Common Stock issued under the 2023 Equity Incentive Plan that has been granted to the Reporting Person as compensation for serving on the Gentherm Board of Directors. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 21:37 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to Buy) · Derivative | 407,364 | $0.00 Strike: $26.65 | $0.00 |
DisclosureSEC source: 0001062993-23-000628 · form4.xml · derivative · entry 5 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 616,676 Underlying: Common Stock · 407,364 shares Expires 2023-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 21:37 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 255,837 | $84.39 | $21,590,084.43 |
DisclosureSEC source: 0001062993-23-000628 · form4.xml · nonDerivative · entry 2 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,113,139 Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 21:37 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 407,364 | $26.65 | $10,856,250.60 |
DisclosureSEC source: 0001062993-23-000628 · form4.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,368,976 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes (i) 11,448 shares of restricted stock for which the risk of forfeiture will lapse on August 5, 2023; and (ii) 14,248 shares of restricted stock for which the risk of forfeiture will lapse as to 7,128 shares on each of August 6, 2023 and August 6, 2024. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 21:23 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $378.08 | $0.00 |
DisclosureSEC source: 0001437749-22-020846 · rdgdoc.xml · derivative · entry 10 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2029-08-15 F5 · derivative.exercise_date: 150,000 options vest in full or in part on 7/1/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator), and 150,000 options vest in full or in part on 7/1/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 21:23 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 13,225 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-020846 · rdgdoc.xml · derivative · entry 9 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,225 Underlying: Common Stock · 13,225 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F4 · derivative.exercise_date: 4,408 shares vest on each of 8/15/2023 and 8/15/2025, and 4,409 shares vest on 8/15/2024. F4 · derivative.expiration_date: 4,408 shares vest on each of 8/15/2023 and 8/15/2025, and 4,409 shares vest on 8/15/2024. Read SEC document |
| August 07, 2022 Filed Aug 9, 2022 22:58 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 16,937 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-019663 · rdgdoc.xml · derivative · entry 9 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,937 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F4 · derivative.exercise_date: On 8/7/2022, the Board of Directors certified vesting of 16,937 performance RSUs. F4 · derivative.expiration_date: On 8/7/2022, the Board of Directors certified vesting of 16,937 performance RSUs. Read SEC document |
| August 07, 2022 Filed Aug 9, 2022 22:58 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 11,557 | $382.97 | $4,425,984.29 |
DisclosureSEC source: 0001437749-22-019663 · rdgdoc.xml · nonDerivative · entry 2 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,403 F1 · balance_after: Includes (i) 2,862 shares of restricted stock for which the risk of forfeiture will lapse on August 5, 2023; and (ii) 3,562 shares of restricted stock for which the risk of forfeiture will lapse as to 1,782 shares on each of August 6, 2023 and August 6, 2024. Read SEC document |
| August 07, 2022 Filed Aug 9, 2022 22:58 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 16,918 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-019663 · rdgdoc.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,960 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes (i) 2,862 shares of restricted stock for which the risk of forfeiture will lapse on August 5, 2023; and (ii) 3,562 shares of restricted stock for which the risk of forfeiture will lapse as to 1,782 shares on each of August 6, 2023 and August 6, 2024. Read SEC document |
| July 28, 2022 Filed Aug 1, 2022 22:11 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Option (right to buy) · Derivative | 45,346 | $0.00 Strike: $108.49 | $0.00 |
DisclosureSEC source: 0001415889-22-008078 · form4-08012022_030829.xml · derivative · entry 5 Kummeth Charles R. · CIK 0001534980 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,346 shares Expires 2022-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| July 28, 2022 Filed Aug 1, 2022 22:11 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 27,707 | $380.76 | $10,549,717.32 |
DisclosureSEC source: 0001415889-22-008078 · form4-08012022_030829.xml · nonDerivative · entry 2 Kummeth Charles R. · CIK 0001534980 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,042 F1 · balance_after: Includes (i) 3,763 shares of restricted stock for which the risk of forfeiture will lapse on August 7, 2022; (ii) 5,724 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2022 and August 5, 2023; and (iii) 5,344 shares of restricted stock for which the risk of forfeiture will lapse as to 1,782 shares on August 6, 2022 and as to 1,781 shares on each of August 6, 2023 and August 6, 2024. Read SEC document |
| July 28, 2022 Filed Aug 1, 2022 22:11 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 45,346 | $108.49 | $4,919,587.54 |
DisclosureSEC source: 0001415889-22-008078 · form4-08012022_030829.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,749 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes (i) 3,763 shares of restricted stock for which the risk of forfeiture will lapse on August 7, 2022; (ii) 5,724 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2022 and August 5, 2023; and (iii) 5,344 shares of restricted stock for which the risk of forfeiture will lapse as to 1,782 shares on August 6, 2022 and as to 1,781 shares on each of August 6, 2023 and August 6, 2024. Read SEC document |
| July 06, 2022 Filed Jul 8, 2022 21:18 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $108.49 | $0.00 |
DisclosureSEC source: 0001415889-22-007599 · form4-07082022_020741.xml · derivative · entry 5 Kummeth Charles R. · CIK 0001534980 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,346 Underlying: Common Stock · 50,000 shares Expires 2022-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| July 06, 2022 Filed Jul 8, 2022 21:18 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 30,935 | $362.78 | $11,222,599.30 |
DisclosureSEC source: 0001415889-22-007599 · form4-07082022_020741.xml · nonDerivative · entry 2 Kummeth Charles R. · CIK 0001534980 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,403 F1 · balance_after: Includes (i) 3,763 shares of restricted stock for which the risk of forfeiture will lapse on August 7, 2022; (ii) 5,724 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2022 and August 5, 2023; and (iii) 5,344 shares of restricted stock for which the risk of forfeiture will lapse as to 1,782 shares on August 6, 2022 and as to 1,781 shares on each of August 6, 2023 and August 6, 2024. Read SEC document |
| July 06, 2022 Filed Jul 8, 2022 21:18 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 50,000 | $108.49 | $5,424,500.00 |
DisclosureSEC source: 0001415889-22-007599 · form4-07082022_020741.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,338 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes (i) 3,763 shares of restricted stock for which the risk of forfeiture will lapse on August 7, 2022; (ii) 5,724 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2022 and August 5, 2023; and (iii) 5,344 shares of restricted stock for which the risk of forfeiture will lapse as to 1,782 shares on August 6, 2022 and as to 1,781 shares on each of August 6, 2023 and August 6, 2024. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 21:05 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Option (right to buy) · Derivative | 5,104 | $0.00 Strike: $108.49 | $0.00 |
DisclosureSEC source: 0001415889-22-006391 · form4-06092022_020617.xml · derivative · entry 5 Kummeth Charles R. · CIK 0001534980 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,346 Underlying: Common Stock · 5,104 shares Expires 2022-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 21:05 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 5,104 | $365.00 | $1,862,960.00 |
DisclosureSEC source: 0001415889-22-006391 · form4-06092022_020617.xml · nonDerivative · entry 2 Kummeth Charles R. · CIK 0001534980 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,338 F1 · balance_after: Includes (i) 3,763 shares of restricted stock for which the risk of forfeiture will lapse on August 7, 2022; (ii) 5,724 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2022 and August 5, 2023; and (iii) 5,344 shares of restricted stock for which the risk of forfeiture will lapse as to 1,782 shares on August 6, 2022 and as to 1,781 shares on each of August 6, 2023 and August 6, 2024. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 21:05 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 5,104 | $108.49 | $553,732.96 |
DisclosureSEC source: 0001415889-22-006391 · form4-06092022_020617.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,442 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes (i) 3,763 shares of restricted stock for which the risk of forfeiture will lapse on August 7, 2022; (ii) 5,724 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2022 and August 5, 2023; and (iii) 5,344 shares of restricted stock for which the risk of forfeiture will lapse as to 1,782 shares on August 6, 2022 and as to 1,781 shares on each of August 6, 2023 and August 6, 2024. Read SEC document |
| June 02, 2022 Filed Jun 6, 2022 16:05 UTC | Gentherm Inc THRM · Entity 4845 | GrantCommon Stock | 1,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-034446 · doc4.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,761 F1 · security: The shares represent Restricted Common Stock issued under the 2013 Equity Incentive Plan that has been granted to the Reporting Person as compensation for serving on the Gentherm Board of Directors. Read SEC document |
| January 28, 2022 Filed Feb 1, 2022 21:35 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to Buy) · Derivative | 799 | $0.00 Strike: $125.05 | $0.00 |
DisclosureSEC source: 0001437749-22-002103 · rdgdoc.xml · derivative · entry 7 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,771 Underlying: Common Stock · 799 shares Expires 2024-08-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| January 28, 2022 Filed Feb 1, 2022 21:35 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to Buy) · Derivative | 938 | $0.00 Strike: $106.59 | $0.00 |
DisclosureSEC source: 0001437749-22-002103 · rdgdoc.xml · derivative · entry 6 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,010 Underlying: Common Stock · 938 shares Expires 2023-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| January 28, 2022 Filed Feb 1, 2022 21:35 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 799 | $125.05 | $99,914.95 |
DisclosureSEC source: 0001437749-22-002103 · rdgdoc.xml · nonDerivative · entry 4 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,338 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes (i) 3,763 shares of restricted stock for which the risk of forfeiture will lapse on August 7, 2022; (ii) 5,724 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2022 and August 5, 2023; and (iii) 5,344 shares of restricted stock for which the risk of forfeiture will lapse as to 1,782 shares on August 6, 2022 and as to 1,781 shares on each of August 6, 2023 and August 6, 2024. Read SEC document |
| January 28, 2022 Filed Feb 1, 2022 21:35 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 938 | $106.59 | $99,981.42 |
DisclosureSEC source: 0001437749-22-002103 · rdgdoc.xml · nonDerivative · entry 3 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,539 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes (i) 3,763 shares of restricted stock for which the risk of forfeiture will lapse on August 7, 2022; (ii) 5,724 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2022 and August 5, 2023; and (iii) 5,344 shares of restricted stock for which the risk of forfeiture will lapse as to 1,782 shares on August 6, 2022 and as to 1,781 shares on each of August 6, 2023 and August 6, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.